Articles by Jason Hafron, MD
The panel concludes with thoughts on the evolving role of lutetium-177 in metastatic castration-resistant prostate cancer.
The panel explores ARANOTE, ARASENS, and PEACE-1, emphasizing drug tolerability, toxicity trade-offs, and more.
The panel breaks down the growing role of MDT and the evolving use of radiation in oligometastatic disease.
The panel considers the ARANOTE trial of darolutamide, emphasizing its tolerability and broad eligibility criteria.
The panel examines the nuances of selecting triplet vs doublet therapy for patients with high-volume or high-risk disease.
The panel discusses how PSMA PET imaging is changing disease classification and decision-making.
The panel begins with how to explain the difference between hormone-sensitive and castration-resistant to patients.
Dr. Hafron breaks down the most important updates in upper tract urothelial carcinoma from the LUGPA 2024 Annual Meeting.
Dr. Jason Hafron provides a detailed real-world explanation of reimbursement considerations for Jelmyto (mitomycin).
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.